ESC 23: Hot Line & Late-breaking Science Video Collection
Published: 04 August 2023
-
Views:
5039 -
Likes:
7
-
Views:
5039 -
Likes:
7
-
Up Next
-
3m 22s
-
4m 1s
-
3m 59sPart 4 | Session 7 HEART-FID: Ferric Carboxymaltose in HF with Iron Deficiency
-
4m 49sPart 4 | Session 8 SurHyb Trial: Hybrid Ablation in Persistent Atrial Fibrillation
-
4m 41s
-
4m 12sPart 4 | Session 10 ILUMIEN IV: OCT Vs Angiography
-
5m 20sPart 4 | Session 11 ReDS-SAFE HF: ReDS-Guided Strategy in Heart Failure
-
5m 23sPart 4 | Session 12 MULTISTARS AMI: Immediate Vs Staged PCI in STEMI and MVD
-
6m 3sPart 4 | Session 13 OCT Vs IVUS Vs Angiography Guidance
-
4m 5sPart 4 | Session 14 OCTOBER: OCT-Guided or Angiography-Guided PCI in Complex Bifurcation Lesions
-
2m 55sPart 4 | Session 15 DANPACE II: Reducing Atrial Pacing in Sinus Node Disease
-
6m 43sPart 4 | Session 16 COP-AF: Colchicine for Perioperative AF
-
4m 33sPart 4 | Session 17 CASTLE-HTx: Catheter Ablation for AF in Pts with Heart Failure
-
4m 53sPart 4 | Session 18 OCTIVUS: OCT Vs IVUS-Guided Percutaneous Coronary Intervention
-
4m 56sPart 4 | Session 19 PUSH-AHF: Natriuresis-Guided Therapy in Acute Heart Failure
-
4m 16s
-
4m 8sPart 4 | Session 21 ONCO DVT: Optimal Duration of DOAC Therapy for IDDVT Patients with Cancer
-
4m 39sPart 4 | Session 22 ATTRibute-CM Trial
-
5m 21sPart 4 | Session 23 RIGHT: Post-PPCI Anticoagulation in STEMI Patients
-
6m 1sPart 4 | Session 24 ARAMIS: Anakinra versus Placebo in Acute Myocarditis
-
4m 9s
-
6m 42sPart 5 | Session 1 Takeaways from ESC 2023 with Dr Cvijic & Dr Grapsa
-
9m 47sPart 5 | Session 2 Takeaways from ESC 2023 with Dr Al-Lamee, Dr Colleran & Dr Paradies
-
3m 33sPart 6 | Session 1 Leadership in Guidelines and Cardiovascular Education with Dr Robert Byrne
-
59sPart 6 | Session 2 Patient Care and Treatment Strategies with Dr Myeong-Ki Hong
-
2m 2s
-
1m 27sPart 6 | Session 4 Intersection of Politics and Medicine with Dr Luengo-Fernandez
-
1m 24sPart 6 | Session 5 Choosing Cardiology and Advice to Researchers with Dr Robert Mentz
-
1m 10sPart 6 | Session 6 Leadership in the Context of Clinical Trials with Dr Michelle O'Donoghue
-
46sPart 6 | Session 7 Trials to Watch Out For with Dr Masahiro Natsuaki
-
49s
-
1m 2sPart 6 | Session 9 Emerging Topics in Electrophysiology with Dr Tobias Reichlin
-
1m 23sPart 6 | Session 10 Key Trials and Data from ESC 23 with Dr Ziad Ali
-
36s
-
58sPart 6 | Session 12 Inspiring Teams with Prof Barbara Stahli
-
2m 21sPart 6 | Session 13 Advice for Early-Career Researchers from Dr Gregg Stone
-
48sPart 6 | Session 14 New Technologies in Electrophysiology with Dr Mads Brix Kronborg
-
1m 25sPart 6 | Session 15 Considering Unmet Needs in Patient Care with Dr Duk-Woo Park
-
59sPart 6 | Session 16 Improving Clinical Practice with Dr Do-Yoon Kang
-
1m 28sPart 6 | Session 17 Contributing to the Guidelines with Dr Jozine Ter Maaten
-
2m 41sPart 6 | Session 18 Emerging Trends in Amyloidosis with Prof Julian Gillmore
-
30sPart 6 | Session 19 Working With Role Models with Dr Yan Yan
-
1m 17sPart 6 | Session 20 The Importance of Mentorship with Dr Giles Montalescot
-
1m 24sPart 6 | Session 21 Personalised Medicine & Team Approach With Dr Christian Sohns
-
1m 51sPart 6 | Session 22 Advancement of EP & Adapting New Approaches With Dr Philipp Sommer
-
2m 14s
-
47m 55sPart 1 | Session 1 ESC 23 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
28m 31sPart 1 | Session 2 ESC 23 Late-breaking Science Preview Joost Daemen, Nicolas M Van Mieghem
-
13m 31sPart 2 | Session 1 The ECLS-Shock Trial Harriette Van Spall, Holger Thiele
-
13m 24sPart 2 | Session 2 The STEP HFpEF Trial Harriette Van Spall, Mikhail Kosiborod
-
9m 37sPart 2 | Session 3 The RECORD MI Registry Harriette Van Spall, Javed Butler
-
30m 23sPart 2 | Session 4 Heart Failure at ESC 2023: Recapitulations, Postulations, Predictions Milton Packer, Harriette Van Spall
-
13m 28sPart 3 | Session 1 Day 1 Highlights: New Guidelines, STEP-HFpEF, COP-AF Mirvat Alasnag, Khaled Al-Shaibi
-
16m 34sPart 3 | Session 2 Day 2 Highlights: BUDAPEST-CRT, FIRE, ECLS-Shock, STOPDAPT-3 Mirvat Alasnag, Khaled Al-Shaibi
-
13m 51sPart 3 | Session 3 Day 3 Highlights: OCT Trials, MULTISTARS-AMI, ATTRibute-CM Mirvat Alasnag, Khaled Al-Shaibi
-
8m 3sPart 3 | Session 4 Day 4 Highlights: OPT-BIRISK & NITRATE-CIN Mirvat Alasnag, Khaled Al-Shaibi
-
6m 46sPart 4 | Session 1 New Guidelines For the Management of Acute Coronary Syndromes Robert A Byrne
-
3m 42sPart 4 | Session 2 NOAH-AFNET 6: Oral Anticoagulation in Pts With AHRE Paulus Kirchhof
-
3m 42sPart 4 | Session 3 LODESTAR: Rosuvastatin Vs Atorvastatin Treatment For CAD Patients Myeong-Ki Hong
Overview
What's hot at the European Society of Cardiology (ESC) Congress 2023?
Browse our curated coverage of the latest updates in cardiology from Amsterdam.
- Watch our View From the Thoraxcenter series for a concise line up of the most awaited trials from Prof Nicolas Van Mieghem and Dr Joost Daemen.
- For a deeper dive into key clinical trial data and its applicability, host, Dr Harriette Van Spall meets with Principal Investigators in her Late-Breaker Discussion series.
- View a condensed summary of the crucial takeaways from each day in our Wrap-Up series with Dr Mirvat Alasnag.
- Our short, accessible Expert Interviews with select faculty focus on data, patient care and the future of their field.
- We will feature personal perspective in Behind the Heart series focusing on career pathways, personal motivations and perspectives on the field.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussions with Dr Harriette Van Spall
Part 3
Daily Wrap-Ups with Dr Alasnag & Dr Al-Shaibi
Part 4
Expert Interviews
Part 5
Women as One & Radcliffe Cardiology Presents
Part 6
Behind the Heart
About the episode
ESC 2023 — Dr Ramón Luengo-Fernández (University of Oxford, UK) joins us on-site to discuss the findings from a registry which aimed to analyse the economic burden of cardiovascular disease within the EU.
This was the first study to utilise Europe-wide patient registries and included the costs of long-term social care. Results from the registry found that cardiovascular disease cost the EU €282 billion in 2021, equivalent to 2% of Europe's gross domestic product. Health and long-term care accounted for €155 billion (55%) of the costs.
Questions:
- What is the importance of this study?
- What methods were used? What were some of the challenges?
- What did you find?
- How did you measure informal care?
- How does this data compare to the cost analysis from 2006?
- What were the key findings from both a public health and economic perspective?
- In your opinion, how should policymakers use this data?
Recorded on-site at ESC Congress 2023, Amsterdam.
Editors: Mirjam Boros and Jordan Rance
Video Specialists: Dan Brent, Tom Green, Mike Knight, Oliver Miles
Comments